<DOC>
	<DOCNO>NCT01275209</DOCNO>
	<brief_summary>This study ass safety efficacy HCD122 ( Lucatumumab ) combine bendamustine patient follicular lymphoma .</brief_summary>
	<brief_title>Study HCD122 ( Lucatumumab ) Bendamustine Combination Therapy CD40+ Rituximab-refractory Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Confirmed diagnosis follicular lymphoma , accord Revised European American Lymphoma/World Health Organization [ REAL/WHO ] classification Documented CD40+ follicular lymphoma Measurable lesion Refractory rituximab Prior treatment least 1 chemotherapeutic regimen 18 year old WHO Performance Status grade 0 , 1 , 2 Life expectancy &gt; 3 month Obtained write informed consent Grade 3b follicular lymphoma evidence indolent lymphoma transform aggressive lymphoma ( i.e . DLBCL ) History another primary malignancy currently clinically significant currently require active intervention Prior allogeneic stem cell transplantation Prior anaphylactic severe infusion reaction patient unable tolerate human immunoglobulin monoclonal antibody administration Impaired cardiac function clinically significant cardiac disease History acute chronic pancreatitis , surgery pancreas , risk factor may increase risk pancreatitis History active infection ( viral , bacterial , fungal ) require systemic therapy within 28 day study treatment . Known diagnosis human immunodeficiency virus ( HIV ) infection Evidence previous hepatitis viral infection hepatitis B hepatitis C Ongoing corticosteroid use ( &gt; 10 mg/day prednisone equivalent ) Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>HCD122</keyword>
	<keyword>Lucatumumab</keyword>
	<keyword>CD40</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Antibody</keyword>
</DOC>